4.7 Review

Biological Age Predictors: The Status Quo and Future Trends

期刊

出版社

MDPI
DOI: 10.3390/ijms232315103

关键词

biological age; molecular clock; age-related diseases; life expectancy; COVID-19

资金

  1. Centre for Strategic Planning and Management of Biomedical Health Risks

向作者/读者索取更多资源

There is currently no universal biomarker to accurately estimate overall health status and life expectancy. Consensus has not been reached on the concept of aging and its assessment methods. However, markers of aging have the potential to improve health control, provide more accurate life expectancy estimates, and enhance overall health and quality of life. Clinicians commonly use certain indicators that may serve as biomarkers of aging, and models combining these markers have shown promise in accurately assessing biological age and the pace of aging.
There is no single universal biomarker yet to estimate overall health status and longevity prospects. Moreover, a consensual approach to the very concept of aging and the means of its assessment are yet to be developed. Markers of aging could facilitate effective health control, more accurate life expectancy estimates, and improved health and quality of life. Clinicians routinely use several indicators that could be biomarkers of aging. Duly validated in a large cohort, models based on a combination of these markers could provide a highly accurate assessment of biological age and the pace of aging. Biological aging is a complex characteristic of chronological age (usually), health-to-age concordance, and medically estimated life expectancy. This study is a review of the most promising techniques that could soon be used in routine clinical practice. Two main selection criteria were applied: a sufficient sample size and reliability based on validation. The selected biological age calculators were grouped according to the type of biomarker used: (1) standard clinical and laboratory markers; (2) molecular markers; and (3) epigenetic markers. The most accurate were the calculators, which factored in a variety of biomarkers. Despite their demonstrated effectiveness, most of them require further improvement and cannot yet be considered for use in standard clinical practice. To illustrate their clinical application, we reviewed their use during the COVID-19 pandemic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据